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Abstract
The identification of several hundred genomic regions affecting disease risk has proven the ability of
genome-wide association studies have proven their ability to identify genetic contributors to
disease. Currently, single-nucleotide polymorphism (SNP) association analysis is the most widely
used method of genome-wide association data, but recent research shows that multi-marker tests
of association may provide greater power, especially when more than one mutation is present
within a gene and the mutations are in low linkage disequilibrium with each other. Here we use a
multi-marker association test based on regression to SNPs located within known genes to obtain a
gene-level score of association. We then perform pathway analysis using this score as a measure of
gene importance. We use two tests of pathway enrichment - a binomial test and a random set
method. By utilizing publicly available gene and pathway information, we identify B cell, cytokine
and inflammation response, and antigen presentation pathways as being associated with rheumatoid
arthritis. These results confirm known biological mechanisms for auto-immunity disorders, of
which rheumatoid arthritis is one.
Background
Rheumatoid arthritis (RA) is a complex genetic auto-
immune disease that is characterized by pain and
swelling in the joints of the body [1]. According to the
National Institute of Arthritis and Musculoskeletal and
Skin Diseases [2], about 1.3 million adults in the U.S.
suffer from RA. While the exact cause of the disease is
unknown, it is believed that it is due to three basic
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to identify the genetic factors involved, researchers have
performed many linkage and association studies. These
studies have implicated several genetic contributors,
many of which have not been replicated. One region
that has been replicated is the association of the major
histocompatibility complex (MHC) on chromosome 6,
with HLA_DRB1 alleles consistently found to be
associated with RA [3]. Other genetic contributors that
have more recently been identified and verified, primar-
ily thanks to the increased power and localization
provided by genome-wide association studies (GWAS),
are PTPN22 and TRAF1-C5 [4].
GWASarebestsuitedfo ridentifyingcommonalleles with
small to moderate effects on complex disease risks. To
date, several research groups have undertaken this
approach to identify the genetic components of RA.
Here we concentrate on the GWAS performed by Plenge
et al. [4]. Their study successfully combined the inter-
rogation of hundreds of thousands of SNPs, a well
defined clinical outcome, and high-quality control
standards to identify the association of TRAF1-C5 and
confirm the association of PTPN22 and MHC,e a c h
attaining a significance level < 5 × 10
-8. The ability of
the study to replicate known results and to identify new
associations highlights the good design of the study, and
therefore may provide power for additional findings with
further, more refined analysis. Here, we will apply known
biological information to the analysis, namely gene and
pathway annotation.
Given the success of gene and pathway analysis of gene
expression data [5], Wang et al. applied similar
methodology to a GWAS on Parkinson’s disease. Their
method used the maximum test statistic of all SNPs
located near or on a gene as the gene-level score. They
then modified the gene set enrichment analysis (GSEA)
algorithm [6], previously used for gene expression
studies, to identify enriched pathways that are associated
with the disease. GSEA applies a windowed Kolmo-
gorov-Smirnov test to a ranked list of genes (ordered by
the association test above) to determine whether a
predefined set of genes is enriched compared with a
random selection of genes. Using similar pathway
information but different methods, we attempted to
identify pathways responsible for RA. We employed
regression as a test for multi-marker association to
generate a gene-level score, and the binomial approx-
imation of Fisher’s exact test to identify enrichment of
biological pathways. Regression has been shown to be a
more powerful method than single-SNP (single-nucleo-
tide polymorphism) analysis due to its ability to exploit
linkage disequilibrium [7] and will be computational
faster than using the best-scoring SNP followed by
permutation to obtain a p-value. Lastly, we implemented
a random set gene enrichment method [8] and com-
pared the pathways identified by both methods.
Methods
The first step in our method is to calculate a gene-level
score. In order to perform the linear regression, we
converted the text genotypes into a numeric genotype
score (0, 1, or 2) based on the count of the minor allele.
SNPs with a minor allele frequency < 0.01 or a p-value
< 0.001 for Hardy-Weinberg equilibrium were excluded
from the analysis. Additionally, only SNPs and subjects
who had <10% missing values were included. Our
analysis included 528,719 autosomal SNPs for 2,002
subjects (862 cases and 1140 controls) following the
quality control filtering. The SNP were then mapped to
known genes. Gene information (gene symbol, chromo-
some, start position, and end position) present in the
Refseq annotation was downloaded from NCBI [9] for
build 38. SNPs were considered to be on a gene by using
the SNP annotation file provided by Plenge et al. [4] for
Genetic Analysis Workshop 16. For each gene, we
queried the SNP genotypes associated with the gene
a n dr e g r e s s e dc a s e - c o n t r o ls t a t u so n t ot h eS N Pg e n o t y p e
v a l u e s .T h eg e n es c o r ei st h ep-value of this multiple
regression. We obtained gene-level scores for 15,107
genes.
In order to determine the enrichment of pathways, we
gathered publicly available pathway information from
three public databases: KEGG [10], GenMAPP [11], and
BioCarta [12]. The pathways were downloaded from
each database and aggregated. There were a total of 564
pathways comprising a total of 5,464 unique genes.
Pathways ranged in size from 1 to 399 genes, had a
median number of 28 genes, and averaged 47 genes per
pathway. We did not require there to be a minimum
number of genes in order to be considered a pathway.
Pathway enrichment was determined using two different
methods, a binomial test and a random set method. The
binomial test is an approximation to the Fisher’se x a c t
test, in which the p-value of enrichment is determined
from the hypergeometric distribution. This approxima-
tion has been shown to be robust and dependable in
previous studies of enrichment using gene expression
data [13]. The probability of success for the binomial
distribution was calculated by setting a threshold level
below which a gene is considered ‘significant’,t h e n
calculating the fraction of all gene scores below this
threshold level. The significance of each pathway was
calculated by computing the fraction of genes within the
pathway below the threshold used above, the size of the
pathway, and the probability of success determined by
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the arbitrary threshold of significance chosen, we used
three different threshold of significance (0.01, 0.1, and
0.2) and compared their results.
The second method, the random set method, computes a
test statistic equal to the negative of the sum of the log
(p-values) for each gene in the pathway [4]. The
significance of the pathway is determined by permuting
the gene scores, then recalculating the test statistic for
each pathway. This permutation procedure was per-
formed 10,000 times, and the p-value of enrichment was
set equal to the number of random sets based on
permutation that had a test statistic less than the
observed original data. This statistic will be more
influenced by better scoring genes than the binomial
method. For example, if a pathway contains one very
significant gene (a multiple regression p-value near zero)
or many genes with gene scores that are slightly above a
significance threshold, then the pathway is more likely to
be deemed significant using this method than the
binomial. In the binomial setting, it is necessary to
have several genes deemed significant below the set
threshold in order to be significant. We anticipate that
the random set method may identify more significant
pathways than the binomial method, especially when
the MHC region is included. We performed the pathway
analysis including and excluding the MHC region in
order to compare the ability of these methods to identify
RA-related pathways.
Due to the inherent correlation among genes due to
linkage disequilibrium, the pathway enrichment p-values
are not independent and require an estimate of the false-
discovery rate. We calculated a measure of the false-
discovery rate by performing a permutation procedure as
follows. Gene scores were recalculated 1000 times using
permuted disease status. For each set of gene scores, the
pathway analysis (binomial at each threshold and the
random set method) was performed using all genes, and
using non-MHC genes. The false-discovery rate was
obtained by counting the number of pathways with a
p-value less than that obtained using the real data for
each iteration and taking the average over the permuta-
tions. We use this value, approximately equal to the
false-discovery rate, to determine the significance of each
pathway.
Results
T h en e g a t i v el o go ft h eg e n es c o r e sr e l a t i v et ot h e i r
genomic location are shown in Figure 1. There are a total
of 15,107 genes. The highest scoring genes were HLA-
DRB1 and HLA-DRA: both had regressions resulting in a
p-value of approximately 0. The log values of these
p-values were set to 300 for Figure 1. The top 100 genes
were primarily in the 6p21 region, which represents the
MHC region. The top-scoring gene outside of the MHC
region was CDC25C on chromosome 5. Of the five
known genes associated with RA, HLA-DRB1 tied for the
highest rank, PTPN22 ranked 83
rd, TRAF1 ranked 119
th,
C5 ranked 631
st,a n dSTAT4 ranked 3,182
nd.A l lb u to n e
of these genes had a high-scoring SNP within the gene.
HLA-DRB1 had the highest single-SNP association score
of all SNPs tested; it had a chi-square test statistic of
500.4. The highest single-SNP chi-square values for the
other known genes are: 42.97 (PTPN22), 30.31 (TRAF1),
32.10 (C5), and 6.30 (STAT4). Many genes have been
reported to have an association to RA in different studies,
but their true association status is not definite. Among
them are IKBL, BAT2, CTLA4, PADI4, TNFAIP3, CD40,
BDKR1,a n dCCL1. The ranks of these potential RA genes
by gene score are 145, 19, 421, 1550, 666, 1951, 2348,
and 69, respectively. Figure 2 shows the overall
distribution of gene scores. We did not observe larger
genes having more significant gene scores. A regression
of the count of SNPs within the gene (we assumed larger
genes would have more SNPs contained within their
boundaries) onto the gene score resulted in a p-value
of 0.18.
Genes assigned to pathways do not equally represent the
genomic regions. Specifically, the genomic regions
containing the highest gene scores differed between
those identified overall and those located in pathways;
however, the gene region with the highest number of
genes located within it was the same for both the
pathway regions and overall regions - 6p21.3 (the MHC
region). At the 0.01 threshold level, five of the top ten
genomic regions were the same. Six of the top ten
regions were the same at the 0.1 threshold level, and
seven out of ten at the 0.2 threshold level. Table 1 lists
the top ten regions represented when considering all
genes compared with using only genes within the
pathways. The regions do vary by the threshold chosen,
with only 6p21.3 remaining at the top for each thresh-
old. This region (MHC) is known to be associated with
RA, and also represents the only region definitely linked
to RA in family-based linkage studies [14]. Other regions
that have shown suggestive linkage in past family studies
(1p13, 1q41-43, 6q16, 16p, and 18q) are not repre-
sented. In order to assess the impact of genomic region
6p21.3 on the pathway results, we removed all 156 genes
l o c a t e di nt h er e g i o na n dr e c a l c u l a t e dt h ep a t h w a ys c o r e s
using the three thresholds. Despite the lack of spatial
equality of the genome in the pathway tests, the percent
of genes used by the binomial test were consistent across
the different thresholds. Specifically, there were 1101 out
of the total 15,107 genes with a gene score < 0.01; 352 of
these genes were located in the pathway annotation.
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threshold of 0.1, 3957 genes had gene scores below 0.1,
of which 1258 were located in pathways. When the
threshold was set to 0.2, 6040 genes had scores below
the cut-off and 1915 of them were located within the
pathway annotation. Hence, approximately 32% of
overall genes were consistently located in annotated
pathways irrespective of the threshold chosen.
The significant pathways from our analysis are reported
in Additional files 1 and 2. The pathways shown had a
binomial or random set false-discovery rate estimated
from our permutation procedure < 0.01. The top-scoring
pathways were consistent across the methods and were
related to the immune response, which defines RA. The
pathways that were significant at each of the binomial
thresholds as well when using the random set method
are: BioCarta’s Bystander B Cell Activation Pathway,
Biocarta’s Antigen Dependent B Cell Activation Pathway,
KEGG’s Antigen Processing and Presentation Pathway,
BioCarta’s IL 5 Signaling Pathway, BioCarta’s Lck and
Fyn Tyrosine Kinases in Initiation of TCR Activation
Pathway, BioCarta’s Human Activation of Csk by cAMP-
dependent Protein Kinase Inhibits Signaling Through the
T Cell Receptor Pathway, BioCarta’sH u m a nC y t o k i n e
and Inflammatory Response Pathway, and BioCarta’s
Humna Th1/Th2 Differentiation Pathway. The genes that
make up these pathways are, however, primarily located
in the MHC region. The only top pathway not
dominated by genes in the MHC region is GenMAPP
Human Adipogenesis. After removing the 156 genes
located in 6p21.3, some of the previously top-scoring
pathways associated with B Cell Activation and Antigen
Processing and Presentation were no longer significant
when using the binomial test. The only pathway that was
significant across the board following the removal of
6p21.3 genes was GenMAPP Human Adipogenesis.
Interestingly, even when the MHC region genes were
removed, the random set method continued to identify
many of the immune-related pathways identified by
both methods before the removal of 6p21.3 genes.
As expected, the random set method identified more
pathways than the binomial method using all genes and
when MHC region genes were removed. The random set
method identified 34 pathways as significant compared
with 15, 13, and 14 for the binomial when a threshold of
0.01, 0.1, and 0.2 were used, respectively. The same was
Figure 1
Plot of all gene scores relative to gene position. Plot of -log(p-value) of the multiple regression p-value for each gene at
its relative position in the genome.
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pathway significance was assessed again; however, the
difference was more dramatic. The random set method
identified 50 pathways as significant, while the binomial
identified only 2, 6, and 7 for the 0.01, 0.1, and 0.2
thresholds. This change, an increased number found by
random set and decreased number identified by the
binomial test, reflects how each method determines
significance. For the binomial test, the removal of
significant genes lessens the probability that a pathway
will have genes that are below the set threshold, resulting
in fewer pathways being identified. In contrast, the
Table 1: Top ten genomic regions interrogated by pathways
Threshold
0.01 0.1 0.2
Rank Pathway
a Overall
b Pathway Overall Pathway Overall
1 6p21.3 6p21.3 6p21.3 6p21.3 6p21.3 6p21.3
2 6p22.1 19p13.3 21q22.3 19p13.3 1q21 19p13.3
3 6p21 6p22.1 5q31 21q22.3 19q13.2 16p13.3
4 13q34 6p21.33 19p13.2 16p13.3 19p13.3 21q22.3
5 16q22.1 16q22.1 16p13.3 19p13.2 16p13.3 19p13.2
6 6p21.31 17q12 11p15.5 11p15.5 21q22.3 14q11.2
7 16p11.2 21q22.3 11q13 14q11.2 19p13.2 1q32.1
8 2q33 2q11.2 19p13.3 17q25.1 19q13.1 19q13.2
9 19q13.4 14q11.2 1q21 11q11 11p15.5 11p15.5
10 1q21 6p21 17p13.1 19q13.2 5q31 11q11
aPathway, only genes within the pathway were considered.
bOverall, all genes were considered.
Figure 2
Histogram of gene score enrichment. Histogram of gene scores (multiple regression p-values) for genes containing SNPs
in the study.
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genes that are available. In effect, there is less competi-
tion for pathways containing one or two significant
genes compared to random sets of genes, and this leads
to more pathways classified as significant.
Discussion
Applying pathway annotation information to the analy-
sis of GWAS data may lead to a better biological
understanding of the disease being studied [15]. RA is
a systemic autoimmune disease. Our bodies typically
initiate an immune response when foreign invaders
(antigens) enter our bodies. Antibodies that have been
produced by B cells identify antigens; these antibodies
have an antigen-binding region and a tail region that
binds to receptors on macrophages. Macrophages are
built to engulf and destroy these invaders, but they also
produce cytokines (proteins used to communicate to
other cells that an antigen has been found) like tumor
necrosis factor (TNF) and interleukin (IL)-1, and signal
the adaptive immune system (T-cells) using MHC
proteins that an infection is underway. These MHC
class II molecules are used to communicate to helper
T-cells the state of a current infection. The type of
infection will determine the type of helper T-cell that is
activated and hence the kind of cytokines that will be
produced. Type 1 helper T-cells (Th1) typically produce
IFN-g, IL-2, and TNF, while Type 2 helper T-cells (Th2)
produce IL-4, IL-5, and IL-10. When RA affects someone,
the balance in this response is disturbed-the immune
response is activated when antibodies recognize self cells
as invaders, which then activate macrophages. The
inflammation found in RA pa t i e n t si sc a u s e db yt h e
abundance of TNF from this immune response. In fact,
treatments for RA try to block production of TNF [16].
Risk of RA has both genetic and environmental
components. The exact mechanism of RA is unknown,
but several genes and pathways have been identified. For
e x a m p l e ,s m o k i n gi sak n o w nr i s kf a c t o r .S m o k i n gc a n
cause a post-translational modification of some proteins,
which results in a higher binding affinity by HLA-DRB1
(A MHC class II molecule) and leads to an exaggerated
helper T-cell response [17]. Variants of the gene PTPN22
have been shown to lead to a predisposition of
autoimmunity by effecting the removal of auto-reactive
T-cells [18]. Additionally, the activation of STAT4 by IL-
12 can bias the production of Th1 and Th17 from virgin
T-cells instead of Th2 [18]. The Th1/Th17 inflammatory
response leads to an accumulation of the cytokine TNF,
which is a signature of RA [18].
Our gene scores corroborate these known results, in
particular the association with the MHC region. The top
two scoring genes were HLA-DRA and HLA-DRB1. Alleles
of HLA-DRB1 have been identified by others to be
associated with RA. The shared-epitope hypothesis
describes which of the particular MHC class II molecules
are associated with RA susceptibility and RA severity [3].
In Figure 2, the enrichment of genes with low p-values is
apparent. Given this enrichment, we believe that there is
relevant biological information on which to capitalize.
Other previously reported genes associated with RA did
have high ranks in our analysis. For example, PTPN22
ranked 83
rd and TRAF1 ranked 119
th. STAT4,h o w e v e r ,
did not rank highly, but the authors who provided the
data used a combined data set in order to find that
association. The highest non-MHC gene was CDC25C,
which ranked 30
th. No current research associates
CDC25C to RA, but it does interact with Lck - a tyrosine
kinase involved in TCR activation [19].
The pathway results support the known biological
processes involved in RA. Using the 0.01 threshold and
sorting by their significance, we found pathways for
antigen processing and presentation, B cell activation,
T cell activation, and the complement pathway at the
top. The approximately 156 genes in the MHC region
dominate these pathways. But, each of these pathways is
integral to the immune response. Exploring the remain-
ing pathways in Supplemental File 1 [1753-6561-3-S7-
S91-S1.pdf], we see several other pathways that relate to
other known theories of RA. For example, a case could be
made for BioCarta’s Human Extrinsic Prothrombin
Activation Pathway. Animal studies have shown that
cartilage degeneration due to joint immobilization
increases the expression of prothrombin gene in chon-
drocytes [20]. Additionally, findings showing the pro-
and anti-inflammatory properties of adipose tissue make
GenMAPP’s Human Adipogenesis Pathway a likely
candidate for RA [21]. Lastly, removing the genes located
in the 6p21.3 region did remove the most significant
pathways associate with B cell activation, but many other
potential pathological pathways remained, specifically
the Adipogenesis Pathway. While the cell cycle pathways
were not unanimously significant, their presence follow-
ing the removal of 6p21.3 was striking considering their
known role in RA [22].
Conclusion
Here we have demonstrated the methods and usefulness
for applying gene and pathway annotation information
to GWAS. We performed a multiple regression of case-
control status onto all SNPs located within a gene to
generate a gene-level score of association. Regression has
shown to be a powerful method of multi-locus associa-
tion, especially when there is little to no linkage
disequilibrium among the SNPs [23]. Our results show
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known genes associated with the disease. Given this
confirmation of available information, we used these
gene-level scores as a basis for identifying pathways
associated with RA disease status. By using different
thresholds in our analysis, we were able to evaluate the
genes at different interest levels. Here the results were
consistent across different thresholds, and were corro-
borated by pathways identified by the random set
method. This overlap may not be found in every study,
and may be due to the strong signal present at MHC. We
suspect that by choosing different thresholds, researchers
will be able investigate the impact of genes at different
association levels. Given that pathway-based analysis is
not the first pass researchers will use to identify
associations, it does provide a means to mine informa-
tion present not captured by single-SNP analysis.
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